TD Cowen Downgrades Novo Nordisk on Concerns over Semaglutide Patent Loss, Pipeline Outlook

Why It Matters

The downgrade underscores growing earnings pressure as Novo Nordisk may lose its GLP‑1 market dominance, reshaping the obesity and diabetes therapeutic landscape.

Key Takeaways

• TD Cowen cuts Novo Nordisk rating to hold.
• Price target lowered to $42, 6% upside.
• Semaglutide patent expires in multiple markets 2026.
• Pipeline candidates CagriSema, amycretin, ziltivekimab underperform.
• Shares down 22% YTD, 50% past year.

Pulse Analysis

Novo Nordisk has built its recent growth on the blockbuster GLP‑1 drug semaglutide, marketed as Ozempic and Wegovy. While the compound’s patent remains intact in the United States until 2032, it is already expiring in several European and Asian jurisdictions, prompting analysts to anticipate a rapid erosion of pricing power. The loss of exclusivity typically invites a wave of generic and biosimilar entrants, which can compress margins and dilute market share for the original innovator. In this context, the firm’s ability to sustain revenue hinges on the strength of its pipeline and strategic diversification.

The pipeline, however, is showing signs of strain. Novo Nordisk’s next‑generation obesity candidate CagriSema failed to meet primary endpoints, and other late‑stage assets such as amycretin and the anti‑inflammatory ziltivekimab have yet to demonstrate clear differentiation. Without a compelling successor to semaglutide, the company risks losing its duopoly in both diabetes and obesity markets, especially as rivals like Eli Lilly and Pfizer accelerate their own GLP‑1 programs. Branded competition is expected to intensify, potentially accelerating price erosion and shifting prescriber preference toward newer molecules with improved efficacy or safety profiles.

For investors, the downgrade reflects a recalibration of risk versus reward. A modest 6% upside in the revised price target suggests limited near‑term upside, while the stock’s 22% YTD decline signals market skepticism. Novo Nordisk may need to accelerate partnership deals, explore combination therapies, or expand into adjacent therapeutic areas to offset the looming patent cliff. Until a robust pipeline candidate proves its commercial viability, the company’s earnings trajectory will remain vulnerable to competitive pressures and pricing headwinds.